Table of Contents Show
Robotic neuro rehabilitation is no longer a distant aspiration for patients across India’s hospitals and clinics. Rymo Technologies, a Navi Mumbai based healthcare technology startup, has secured ₹10 Crore in a seed funding round led by IAN Angel Fund — the evergreen investment vehicle of IAN Group, India’s largest early stage investment platform with additional participation from angel investors. The development marks a significant milestone for the company as it prepares to scale both domestically and internationally.
A Solution Built for a Growing Crisis
Neurological disorders and stroke related disabilities are rising at an alarming rate globally, yet access to quality rehabilitation remains severely limited. The primary barriers are a chronic shortage of trained therapists and the prohibitive cost of advanced robotic systems challenges that disproportionately affect mid sized hospitals and Tier 1/2 clinics in emerging economies. Rymo Technologies was founded with a deliberate mandate to address precisely this gap.
Established in 2020 by Chirag Shah (CEO) and Abhishek Rai (CTO), the company has developed the Mobi-L system — a multi joint robotic rehabilitation platform that integrates artificial intelligence, virtual reality, and proprietary AI algorithms trained on real patient data. The system delivers personalised therapy protocols, continuously adapting to each patient’s progress and clinical needs, while offering measurable recovery outcomes.
Also Read: Pet Care Brand Moe Puppy Raises ₹2 Crore in Pre-Seed Funding Led by PedalStart
Clinical Validation at Scale
What distinguishes Rymo Technologies from early stage peers is its demonstrable clinical traction. The company has installed 452 devices across 354 institutional clients, including marquee names such as AIIMS, Apollo Hospitals, and Manipal Hospitals. To date, over 7,500 patients have undergone therapy using Rymo’s systems, collectively logging more than 15,000 therapy hours. Clinical studies indicate that patients using the Mobi-L system recover up to 25% faster compared to conventional rehabilitation methods.
The startup has also achieved US FDA classification as a Class II medical device – a credibility marker of significant weight in global healthcare markets and has entered into a distribution partnership with Fourier Rehab to facilitate expansion into ASEAN markets.
What the Funding Unlocks
The ₹10 Crore infusion will be deployed across three strategic priorities: accelerating product innovation, scaling manufacturing infrastructure, and deepening market penetration across India. Beyond domestic growth, Rymo Technologies is actively targeting international expansion into ASEAN nations and the Middle East — regions that share similar healthcare access challenges and represent considerable untapped demand for affordable robotic rehabilitation.
The Road Ahead
Rymo Technologies stands at an inflection point. With institutional validation, proven clinical outcomes, regulatory recognition, and now meaningful capital behind it, the company is well positioned to redefine how neuro rehabilitation is delivered — not just in India, but across the developing world. As the global neuro rehabilitation devices market grows at approximately 14% annually toward a valuation of $2.16 billion, Rymo’s timing, technology, and mission appear well aligned for the journey ahead.
Also Read: DrinkPrime Closes Extended Series A Round Worth ₹20 Crore Led by Mirabilis and Artha Continuum
